Philogen to Present at UBS Global Healthcare Conference
May 05, 2022 07:00 ET
|
Philogen
Philogen to Present at UBS Global Healthcare Conference Siena (Italy), 5 May 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted...
Philogen Reports Full Year 2021 Results and Provides Corporate Update
April 01, 2022 07:00 ET
|
Philogen
Philogen Reports Full Year 2021 Results and Provides Corporate Update Patient enrolment in Nidlegy™’s European Phase III trial for the treatment of Stage IIIB/C melanoma is progressing in line with...
Philochem and Bracco Imaging Announce a Collaboration on the Development of a Small Molecule for Diagnostic or Medical Imaging Applications
March 22, 2022 03:05 ET
|
Philogen
PHILOCHEM AND BRACCO IMAGING ANNOUNCE A COLLABORATION ON THE DEVELOPMENT OF A SMALL MOLECULE FOR DIAGNOSTIC OR MEDICAL IMAGING APPLICATIONS Siena, Italy, 22th March 2022 – Philochem, a subsidiary of...
Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)
January 07, 2022 02:00 ET
|
Philogen
Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) Translational studies performed at the European Institute for...
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS
November 24, 2021 03:00 ET
|
Philogen
PHILOGEN ANNOUNCES NEW COLLABORATION WITH JANSSEN TO DISCOVER SMALL MOLECULE THERAPEUTICS Siena, Italy, November 24, 2021 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody...
Philogen Provides Corporate Update
November 12, 2021 02:00 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun are on track with planned timelines in pivotal clinical trialsFibromun shows potent activity in last-line glioblastoma in combination with...
Philogen Provides Corporate Update
September 29, 2021 04:58 ET
|
Philogen
Philogen Provides Corporate Update Nidlegy™ and Fibromun on track with planned timelines in pivotal clinical trialsUse of Nidlegy™ in non-melanoma skin cancer expanded in Phase II clinical...
Philogen Announces R&D Program Update
July 02, 2021 02:00 ET
|
Philogen
Philogen Announces R&D Program Update Fibromun shows activity in pretreated glioma and sarcoma patients; OncoFAP targets tumor lesions in cancer patients; a new product partnered with AbbVie...
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress
May 12, 2021 13:00 ET
|
Philogen
Philogen Announces First Quarter 2021 Results and Provides Update on Pipeline Progress May 12, 2021 NidlegyTM on track for Phase III European trial in stage IIIB/C melanoma. Opening of additional...